Through AI technology, Neurophet AQUA now provides multiple sclerosis (MS) analysis with a combination of lesion quantification and enhanced segmentation of T2-FLAIR MRI.
The Food and Drug Administration (FDA) has granted expanded 510(k) clearance for multiple sclerosis (MS) assessment with the magnetic resonance imaging (MRI)-based artificial intelligence (AI) software Neurophet AQUA.
Previously FDA-cleared for assessment of brain atrophy on MRI, Neurophet AQUA offers advanced analysis of MS and white matter hyperintensities based off of T2-weighted fluid-attention inversion recovery (FLAIR) MRI, according to Neurophet, the developer of Neurophet AQUA.
Based off brain MRI images, the AI-enabled software Neurophet AQUA reportedly offers quantification of lesions and structural changes associated with multiple sclerosis (MS) and volumetric brain region assessment without the need for 3D T1 images. The Neurophet AQUA software recently garnered expanded FDA 510(k) clearance for MS assessment. (Image courtesy of Adobe Stock.)
The company said key features of the AI-powered software’s MS analysis include:
• precise assessment of lesion count, volume and progression through enhanced quantification of lesions and structural changes;
• volumetric brain region assessment without the need for 3D T1 images; and
• bolstered segmentation of T2-weighted FLAIR images at 2D and 3D on 1.5T and 3T MRI platforms.
"MS is a neurological disorder that heavily relies on MRI for both diagnosis and disease monitoring, and the McDonald criteria, the diagnostic criteria for MS, specifically includes MRI confirmation of lesions disseminated in space and time," said Jake Junkil Been, the co-CEO of Neurophet. "Neurophet AQUA's advanced MS analysis technology significantly enhances efficiency and convenience for healthcare professionals, making it an indispensable tool in both diagnostic and prognostic stages."
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.